Broad-spectrum metastasis suppressing compounds and therapeutic uses thereof in human tumors

Pnina Gottfried Komlosh, Jonathan L. Chen, Jessica Childs-Disney, Matthew D. Disney, Dan Canaani*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

1 Scopus citations

Abstract

Previously, we have identified a novel human metastasis-inducing lncRNA (named SKAI1BC), that suppresses the KAI1/CD82 metastasis-suppressing gene and is upregulated in triple negative breast cancer and melanoma derived cell lines. Modeling of the SKAI1BC lncRNA secondary structure and its potential interaction with Inforna compounds, led us to identify several compounds that might bind the SKAI1BC lncRNA. We found that these compounds inhibit metastasis invasion and cell migration in culture, in all eight types of solid human cancers tested: several of which are the most lethal and/or frequent human malignancies. Moreover, in most cases, the mechanism of action of several of our compounds involves enhancement of KAI1/CD82 RNA level depending on the specific compound and the human tumor type. With the epigenetic inactivation of KAI1/CD82 in at least ten additional solid human cancers, this implies a very good chance to broaden the spectrum of human cancers affected by our compounds. This is the first time that modeling of a large lncRNA (> 700 bp) secondary structure followed by its potential interaction with Inforna like compounds database has led to the identification of potential biologically active small molecule drugs.

Original languageEnglish
Article number20420
JournalScientific Reports
Volume13
Issue number1
DOIs
StatePublished - Dec 2023

Funding

FundersFunder number
National Institutes of HealthR01 GM097455, R01 CA249180

    Fingerprint

    Dive into the research topics of 'Broad-spectrum metastasis suppressing compounds and therapeutic uses thereof in human tumors'. Together they form a unique fingerprint.

    Cite this